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BACKGROUND: It is important to maintain high-quality cancer care while reducing spending. This requires an under-
standing of how stakeholders define ‘‘quality.’’ The objective of this literature review was to understand the percep-
tions patients, physicians, and managed care professionals have about quality cancer care, especially chemotherapy.
METHODS: A computerized literature search was conducted for articles concerning quality cancer care in patients
who received chemotherapy. Among >1100 identified sources, 25 presented interviews/survey results from stakehold-
ers. RESULTS: Patients defined quality cancer care as being treated well by providers, having multiple treatment
options, and being part of the decision-making process. Waiting to see providers, having problems with referrals,
going to different locations for treatment, experiencing billing inaccuracies, and navigating managed care reimburse-
ment negatively affected patients’ quality-of-care perceptions. Providers perceived quality cancer care as making
decisions based on the risks-benefits of specific chemotherapy regimens and patients’ health status rather than
costs. Providers objected to spending substantial time interacting with payers instead of delivering care to patients.
Payers must control the costs of cancer care but do not want an adversarial relationship with providers and patients.
Payers’ methods of managing cancer more efficiently involved working with providers to develop assessment and de-
cision-assist tools. CONCLUSIONS: Delivering quality cancer care is increasingly difficult because of the shortage of
oncologists and rising costs of chemotherapy agents, radiation therapy, and imaging tests. The definition of quality
cancer care differed among stakeholders, and healthcare reform must reflect these various needs to maintain and
improve quality while controlling costs. Cancer 2011;117:884–96. V C 2010 American Cancer Society
KEYWORDS: quality of healthcare, quality indicators, quality assurance, neoplasms/drug therapy, cancer care
facilities, hospital oncology service.
Leading cancerexpertsandorganizationsintheUnitedStatesareseekingwaystoassessqualitycancercareandensure
its delivery because of increasing costs to patients and healthcare plans,
1,2 including rising out-of-pocket costs for cancer
medications.
3 The anticipated shortage of oncologists
4,5 also will challenge the delivery of quality cancer care. According
to theInstituteofMedicine,qualitycare shouldbe consistent withcurrentprofessionalknowledgeabout adisease,includ-
ing its diagnosis, staging, and treatment, and should produce the desired health outcomes.
6 The objective of this literature
review was to identify the perceptions of stakeholders—providers, patients, and payers—of quality cancer care in the
United States, particularlyfor patients who receive chemotherapy. On the basis of these perceptions, thisreview offers sev-
eralrecommendations forimprovingthe qualityofcancer care.
MATERIALS AND METHODS
The PubMed database, the Excerpta Medica Database (EMBASE), and Cochrane Reviews were searched systematically
forpublicationsrelatedtocancer.PubMedmedicalsubjectheading(MeSH)termsincluded‘‘Neoplasms/DrugTherapy’’;
‘‘Neoplasms/Radiotherapy’’; ‘‘Neoplasms/Surgery’’; ‘‘Cancer Care Facilities’’; ‘‘Oncology Service, Hospital’’; and ‘‘Radia-
tion Oncology.’’ MeSH terms to capture studies on quality of care were ‘‘Quality of Health Care’’; ‘‘Quality Assurance,
Health Care’’; and ‘‘Quality Indicators, Health Care.’’ For this study, we reviewed 875 article abstracts and applied inclu-
sion/exclusion criteria (Fig. 1). The primary focus of the study was quality of cancer care for patients who were receiving
chemotherapy. Of the 875 article abstracts, 140 publications of interest were obtained for full review. Two hundred
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Review Articlethirty-six conference abstracts also were identified from
the American Society of Clinical Oncology 2008 and
2009 meetings and from the European Cancer Organiza-
tion/European Society of Medical Oncology 2009 meet-
ing. The conference abstracts were searched using the
following terms: ‘‘quality of healthcare,’’ ‘‘quality of
healthcare,’’ ‘‘quality assurance,’’ ‘‘quality indicators,’’
‘‘quality care,’’ and ‘‘quality of care.’’ Additional articles
were obtained from the selected article bibliographies and
from online searches informed by content from the
selected articles.Online searcheswereneeded in particular
to obtain perspectives of managed care professionals. The
Internet was searched for ‘‘managed care’’ with ‘‘journal’’
to identify publications that specifically addressed man-
aged care, and then the tables of contents were searched
when available online. To ensure a varied managed care
perspective, this review included publications from pro-
fessionals in the field that related their experiences and/or
described their insurance companies’ programs to manage
cancer patients.
RESULTS
Although the quality of cancer care was discussed fre-
quently in conferences and publications, there were few
structured studies that obtained patients’ views, and even
fewer reported interviews with providers and managed
care professionals. In total, 25 sources described surveys
or interviews with patients, providers, or professionals in
managedcaresettings.
Patient Perspectives
Thirteenstudiesreportedpatientperceptionsofqualitycan-
cer care from >9000 patients (Table 1). Five of those 13
studies enrolled exclusively patients with breast cancer (N ¼
1039), whereas1studyenrolled onlypatientswith colorectal
cancer (N ¼ 1067). Four studies included 6905 patients
withanycancer orwith1of severalkinds ofcancer.
Promoters of and barriers to quality care:
Information and interactions
Studies of patient perceptions revealed that patients
report receiving high-quality cancer care when they are
Figure 1. This flow diagram shows the number of abstracts and full-text sources reviewed for the current literature review and
reasons for exclusion. EMBASE indicates Excerpta Medica Database; ASCO, American Society of Clinical Oncology; ECCO, Euro-
pean Cancer Organization; ESMO, European Society for Medical Oncology; PRO, patient-reported outcome.
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ment, participate in decision making, trust their physi-
cian, communicate their feelings to providers, and believe
that care from various professionals is well coordinated
(Table 2). In a study among 613 women aged  67 years
with breast cancer, surgeon-initiated communication and
being presented with multiple treatment options gave
patients the perception of having a choice of treatment.
7
Women who reported high levels of surgeon-initiated
communicationwere2.13timesmorelikelytobesatisfied
with their care than women who reported low levels of
surgeon-initiated communication. Provision of informa-
tion from nurse case managers also led to a higher level of
patient comfort. In a randomized, prospective trial of
women aged  65 years with breast cancer, 169 women
who were assigned a case manager were more likely to per-
ceive that they had a real choice in their treatment com-
pared with166 womenwhodidnot haveacasemanager.
8
Patients were concerned about their personal inter-
actions with providers and were more likely to notice a
lack of positive interactions than the presence of quality
interactions.
9 In an analysis of 3 studies and that included
a total of 259 patients, mean responses to the Holistic
Caring Inventory, which consists of physical, psychologi-
cal, sociocultural, and spiritual domains, indicated that
patients perceived that they received more physical and
sensitive caring than interpretive and spiritual caring from
nurses. Interpretive caring, as defined in the studies,
required that the nurse have more conversations with the
patient’s family, share feelings and information, and be
aware of specific circumstances of the patient’s life to
explain how cancer and treatment would affect these
areas. Nurses may not have time to provide the depth of
interactions required to offer spiritual care. Patients
expressed that they did not expect spiritual care but did
expect to be treated as a unique individual and with care,
gentleness,respect,and attention.
9
When information was difficult to obtain, trust was
limited, or care was not well coordinated, patients experi-
enced reduced quality of care. In a survey of >1000
patients with colorectal cancer, results across all racial and
ethnic groups indicated that the domains of care with the
highest problem scores (indicating poor perceptions) were
reported for health information, treatment information,
psychosocial care, and coordination of care. Lower prob-
lem scores (indicating better perceptions) were reported
for confidence in providers and access to cancer care.
Approximately 50% of patients reported receiving insuffi-
cient health information about changes in their work or
usual activities, relationship with their spouse or partner,
or sexual activity. Approximately 25% to 29% of patients
reported problems that included lack of sufficient infor-
mation regarding treatments, lack of coordination among
providers, and lack of involvement in decision making.
Among patients who were eligible for chemotherapy after
surgery, those who did not receive it were more likely to
report problems with confidence in their providers and
access tocare.
10
Table 1. Sources Reporting Patients’ Perceptions of Quality Cancer Care
Study Study Design Type of Cancer in
Patient Population
Sample
Size
Liang 2002
7 Interview Breast 613
Goodwin 2003
8 Interview Breast 169
Brearley 2009
11 Interview Gastrointestinal 19
Bourjolly 2004
18 Interview
a Breast 33
Wenzel & Steeves 2008
17 Interview Breast 14
Lunik 1996
12 Interview Lymphoma 1
Arora 2009
13 Patient’s recounting Lymphoma 1
Gesell & Gregory 2004
15 Survey/questionnaire Any (16 types) 5907
Ayanian 2005
10 Survey/questionnaire Colorectal 1067
Franco 2009
42 Survey/questionnaire Breast 210
Williams 1998
9 Instrument (HCI) Any 259 (165 With cancer)
Nguyen 2009
43 Instrument (EORTC QLQ-C30/
questionnaire)
Breast, prostate, lung, head
and neck, rectal
686
Anderson & Zwelling 1996
16 Instrument (SERVQUAL) Breast, leukemia, gastrointestinal, any
requiring bone marrow aspiration
147
Total no. of patients 9126 (9032 With cancer)
HCI indicates Holistic Caring Inventory; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire;
SERVQUAL, service quality questionnaire.
aBourjolly and colleagues also interviewed providers.
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stage of disease. In a recent study in the United Kingdom,
interviews with 19 patients who had gastrointestinal can-
cers revealed that, during the initial, acute treatment
phases (diagnosisand 3months after diagnosis), quality of
life, daily function, and treatment-related symptoms were
the most important issues for patients among those inves-
tigated. During the later phases (6 months and 12 months
after diagnosis), patients’ concerns shifted from worries
about physical symptoms to worries about recurrence,
lack of new treatmentoptions, gaining independence, get-
ting clear information on long-term care options, and
socialand financialsurvivorship.
11
Support systems
An essential part of receiving quality cancer care for
patients was feeling that they had a strong support system,
consisting of family and friends who would ask difficult
questions when the patients, for any reason, could
not.
12,13 In addition, family and friends helped patients
avoid potential harm from medication errors, such as
pointing out the existence of a drug allergy that was not
notedinthe patientrecords.
14
Service quality
A survey of almost 6000 cancer outpatients who
received treatment at 23 US hospitals assessed patients’
experiences encompassed under the umbrella of service
quality. The service quality areas with the highest scores
(indicating patient satisfaction) were staff courtesy, clean-
liness of the facility, and staff concern for patient comfort.
The ‘‘likelihood of recommending the hospital’s services
to others,’’ which captured overall satisfaction with service
quality, also received 1 of the highest scores. The areas
Table 2. Patients’ Perception of Relevant Factors for Quality Cancer Care
Factor Reference Source
Promoters of quality care
Communication
Surgeon-initiated communication Liang 2002
7
Better patient-physician communication Franco 2009
42
Knowledge of which provider to approach with questions Franco 2009
42
Other (nonsurgeon) healthcare professionals as source of communication (eg, case
manager)
Goodwin 2003
8
Trust in physician (consistent across races) Franco 2009
42; Schrag 2005
44
Caring behavior and attitudes from nurses (treated with care, gentleness, respect,
and attention)
Williams 1998
9
Better treatment by staff/staff courtesy/staff concern for patient comfort Gesell & Gregory 2004
15; Franco 2009.
42
Support
Strong support system of family and friends Lunik 1996
12; Arora 2009
13; Weingart 2007
14;
Ashing 2003
45
Spiritual support Ashing 2003
45
Multiple treatment options Liang 2002
7
Clean facility Gesell & Gregory 2004
15
Barriers to quality care
Difficulty of attaining the cancer diagnosis Lunik 1996
12; Arora 2009
13
Problems obtaining health information Ayanian 2005
10
Problems obtaining treatment information Ayanian 2005
10
Problems with psychosocial care/patient’s emotional needs not addressed Ayanian 2005
10; Gesell & Gregory 2004
15
Lack of involvement in decision making Ayanian 2005
10
Lack of coordination of care among providers Ayanian 2005
10
Lack of awareness, trust, and familiarity with healthcare system and lack of insur-
ance or transportation among Asian-American women
Ashing 2003
45
Unsafe care (adverse events, close calls, and medical errors) Weingart 2007
14
Service quality incidents (waits and delays in service, poor care coordination, com-
munication issues resulting in lack of access to care)
Weingart 2007
14; Anderson & Zwelling 1996
16;
Ayanian 2005
10; Gesell & Gregory 2004
15
Difficulty reaching staff Gesell & Gregory 2004
15
Billing inaccuracies Anderson and Zwelling
16
Difficulty with managed care tasks Wenzel and Steeves
17
Managing or mediating between the managed care organization and the cancer Wenzel and Steeves
17
Various Perceptions of Cancer Care/Colosia et al
Cancer March 1, 2011 887with the lowest scores (indicating dissatisfaction) were
waiting time, ease of reaching the office staff, and the
degree towhichthe staffaddressed thepatient’semotional
needs.
15
Results from another service quality study indicated
that, from a patient perspective, billing accuracy and wait-
ing times were significant problems.
16 The SERVQUAL
questionnaire was administered to 200 patients at each of
4 clinics (N ¼ 800): medical breast, leukemia, medical
gastrointestinal, and bone marrow aspiration. Across all 4
clinics, the attribute of reliability (which included service
provided at the time promised, sympathetic and reassur-
ing manners, and billing accuracy) was rated consistently
by patients as the most important attribute and also
receivedthelowestratingsin termsof quality.
16
Patient perceptions of US managed care
quality of care
Interviews of patients with breast cancer revealed
that interactions with managed care organizations
(MCOs), including issues with billing accuracy, copay-
ments, and referrals, were a major burden and affected
perceptions of the quality of care.
17 Two major themes
emerged from this research. The first was that patients
had‘‘difficultycompletingmanagedcaretasks’’(involving
issues such as getting a referral; clarifying copayment lev-
els; finding knowledgeable and helpful MCO staff; and
getting assistance with paperwork, billing, and treatment
approvals). In addition, patients perceived a lack of logical
and caring decision making on the part of the MCO.
Delays in determining out-of-pocket expenses resulted in
distress and difficulty in planning future treatments. In
addition to the physical vulnerability associated with their
condition, patients were subject to a financial vulnerabil-
ity related to payment for care, because they worried
about discontinuation of coverage and inability to get fur-
ther treatment if coverage was discontinued. Most
patients expressedalack ofconfidence thattherewouldbe
improvements in the MCO system over time. The second
major theme was problems in ‘‘managing or mediating
between the MCO and the cancer [care providers],’’ in
which patients perceived MCO management and cancer
careasseparateentitiesthathadtobelinkedbythepatient
to achieve the best outcomes. Whereas some patients
accepted assistance from the cancer center about billing
issues when possible, others used a more take-charge
approach and expressed frustration at the extra level of
complication caused by this paperwork. In addition,
patients felt burdened with having to coordinate between
the provider and the payer while also taking care of their
physicalneedsrelated tothedisease.
17
A study by Bourjolly and colleagues
18 that involved
interviews with 33 women who had breast cancer revealed
2 main areas of difficulty with insurance: obtaining refer-
rals and receiving medical services in different locations.
The patients’ primary concern was finding the best care to
treat their disease regardless of the type of insurance they
had.Havingto getreferralswas regardedasavery frustrat-
ingexperience. Noneofthewomenreportedbeingdenied
any treatment options because of insurance restrictions;
however, 1 woman’s insurance refused to pay for a bone
scan becauseof problems withthe referral.Havingvarious
aspects of one’s treatment in different locations based on
insurancerequirementswas observed as an inconvenience.
Although the women received chemotherapy or radiation
treatment at a cancer center, some had to get mammo-
gramsand laboratoryworkatotherlocations.
18
Patient characteristics associated with unfavorable
perceptions of care quality
Three studies identified patient and clinical charac-
teristics that were associated with unfavorable perceptions
of quality care. These characteristics included factors
related to health status, type of treatment, living condi-
tions, and sociodemographic characteristics of the
patients, including age, income level, ethnicity, and lan-
guagespoken (Table3).
Provider Perspectives
Seven studies captured perspectives on aspects of quality
cancer care from >2200 providers (Table 4), including 1
studythatalso surveyedpatients.
18
Physician reports on quality indicators
Three studies were identified that asked physicians
about multidisciplinary care, appropriate receipt of chem-
otherapy,and practice processes.A survey of 312 surgeons
who treated breast cancer in 2 large metropolitan cities
(Los Angeles and Detroit) revealed low use of patient and
practice management processes. Approximately 10% of
surgeons reported that  50% of their patients had multi-
disciplinary physician communication. Only 5% of sur-
geons reported that  50% of their patients were provided
with presurgical decision and care support services (eg,
viewing a video about breast cancer). Surgeons who speci-
alized and surgeonsin teachingprogramswere morelikely
tousepractice management processes.
19
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treated women for primary stage I or II breast cancer to
determine why 21% of the women in an earlier study
20
did not receive adjuvant therapy that would have been
consistent with then current National Comprehensive
Cancer Network (NCCN) guidelines.
21 Underuse of ad-
juvant therapy was highest among African-American
women (34%), followed by Hispanic women (23%), and
white women (16%). Of the original study’s 37 surgeons,
35 were available to be interviewed about the underuse of
adjuvanttherapyforthe119womentheyhadtreated(Ta-
ble 5). For 34% of the women, surgeons did not recom-
mend adjuvant therapy based on valid health
considerations. Lack of physician knowledge was the
underlying reason for adjuvant therapy underuse in 3% of
patients.
22 Another 31% of the women declined adjuvant
therapy. The surgeons were asked about which practical
barriers could have played a role in each of their patients’
decisions to decline therapy, but the respondents often
did not know whether patients had difficulty with various
forms of support. For the 119 women who underused ad-
juvant chemotherapy, physicians did not know their cir-
cumstances in terms of financial support (45%),
emotional support (58%), and social support (57%). The
surgeons also often did not know whether patients were
resistant to receiving adjuvant treatment (56%), under-
stood the risks and benefits of adjuvant therapy (54%), or
wereunabletotolerateadjuvanttherapy (52%).
22
For the remaining 34% of patients, surgeons could
not identify why adjuvant therapy was not administered.
Among these patients, referral to an oncology clinic rather
than a specific oncologist was the only risk factor
Table 3. Predictors of Patient Dissatisfaction With Cancer Care
Predictive Factor Instrument Reference Source
Poor global health in patients with head-and-neck
cancer
EORTC QLQ-C30 for sociodemographic,
clinical characteristics, and quality of life
data; OUT-PATSAT35 for satisfaction with
providers, care organization, and services
Nguyen 2009
43
Receipt of radiotherapy in patients with head-and-neck
cancer
Living alone
a
Young age (<55 y vs >55 y; for physicians’ availability)
High income (for provision of information from nurses)
African-American race (associated with less trust in phy-
sician, perception of greater difficulty with psychoso-
cial care, care coordination, access to care, obtaining
health information)
Five-item questionnaire assessing physician
communication (Franco 2009
42); adapted
Picker Institute survey (Ayanian 2005
10)
Ayanian 2005
10; Franco 2009
42
Asian or Pacific Islander (associated with perception of
greater difficulty with care coordination, access to
care, obtaining health information)
Adapted Picker Institute survey Ayanian 2005
10
Nonwhite
b
Non–English-speaking
b
EORTC QLQ indicates European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; OUT-PATSAT35, The EORTC Cancer Outpa-
tient Satisfaction With Care Questionnaire.
aFor provision of information from physicians and nurses.
bLess likely to rate overall quality of cancer care as excellent or very good.
Table 4. Sources That Reported Providers’ Perceptions of Quality Cancer Care
Reference Study Design Type of Provider Type of Cancer
in Patients Treated
Sample
Size
Bickell 2007
22 Interview Surgeons Breast 35
Bourjolly 2004
18 Interview
a Physicians, nurses business office staff Breast 10
Keating 2008
23 Survey/questionnaire Medical oncologists, surgeons Colorectal 1096
Lamkin 2002
24 Survey/questionnaire Registered nurses specializing in oncology Any 463
Tisnado 2008
26 Survey/questionnaire Medical oncologists, radiation oncologists, surgeons Any 348
Katz 2009
19 Survey/questionnaire Surgeons Breast 312
Genentech 2008
25 Survey/questionnaire Oncologists Any NR
b
Total no. of providers  2264
b
NR indicates not reported.
aBourjolly and colleagues also interviewed patients.
bThe survey for Genentech was mailed to 5000 medical oncologists; the response rate was low, but the number of responses was not reported.
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vant therapy (odds ratio, 4.8; 95% confidence interval,
1.1-21.3; P < .01). Few of the surgeons had mechanisms
in place to determine whether a patient followed through
with a recommended referral or treatment. This may be
because the US healthcare system is relatively nonpatern-
alistic and regards patients as autonomous decision mak-
ers whohavethe skillsto determinetheir owncare.
22
In a physician survey that was conducted by Cancer
Care Outcomes Research and Surveillance Consortium
investigators, both patient and clinician characteristics
influenced the decision to use chemotherapy for older or
sicker patients (Table 5). In the study, 1096 physicians
were asked whether they would recommend chemother-
apy in 6 case scenarios of patients who underwent curative
resection for stage III colon cancer. In linear regression
analyses adjusting for physician and patient characteris-
tics, the strongest predictors of chemotherapy recommen-
dation were patient age (aged 55 years vs 80 years) and the
level of comorbidity (none, moderate congestive heart
failure, or severe congestive heart failure). Physicians were
less likely to recommend chemotherapy when the patient
was both sicker and older (P < .001) (Table 5). In
adjusted analyses, younger physicians were more likely to
recommend chemotherapythan olderphysicians.
23
Workload and quality care
A survey in 2000 of 463 registered nurses (RNs)
who specialized in oncology indicated that nurses believed
that the quality of cancer care had decreased because of
shorter hospital stays. These nurses, who worked in inpa-
tient and outpatientsettings, also indicatedthatboth their
workload and their paperwork had increased during the
previous year. Table 6 compares the mean number of
patients cared for and the perceptions of the appropriate
mean number of patients cared for per shift per RN by
employment setting and type of unit. In all cases, the
mean number of patients cared for was greater than the
number the RNs perceived as being appropriate. Most
inpatient and outpatient RNs (72%) said they believed
that double shifts and overtime work in response to staff-
ingshortfallsharmedthecareof cancerpatients.
24
Table 5. Physician Responses to Questions About Chemotherapy Use
Study Population Queried Quality Measure/Outcome
Bickell 2007
22 Surgeons (n¼35) who treated 119 women for primary stage
I or II breast cancer and who did not receive NCCN
guideline-recommended adjuvant therapy
Reasons offered for not receiving guideline-recommended
therapy: therapy was recommended but patients declined
(31%); therapy was recommended but physician could
not identify a reason for its not being administered (sys-
tem failure; 34%); therapy was not recommended (all
valid health reasons; 34%)
Keating 2008
23 Physicians (n¼1096) were queried about chemotherapy use
in 6 case scenarios
Chemotherapy recommended
Keating 2008
23
Variable Comorbidity Chemotherapy Recommended, Adjusted % of
Physicians
Patient age, y
a
55 None 99
80 None 92.6
55 Moderate CHF 88.6
80 Moderate CHF 47.3
55 Severe CHF 24.9
80 Severe CHF 8.9
P <.001
Physician age, y
b
<40 62.6
40-49 62.2
50-54 62.1
55-59 58.3
‡60 54
P <.001
NCCN indicates National Comprehensive Cancer Network; CHF, congestive heart failure.
aThe strongest predictors of recommending chemotherapy were patient age and comorbidity.
bThe strongest physician predictor for recommending chemotherapy was young age.
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on quality care
Four physicians, 3 nurses, and 3 business office staff
members working with breast cancer patients were inter-
viewed about their views on how managed care impacts
cancer patients. Business office staff spent initial time
helping the patients understand their insurance plans and
how these plans affected their need for referrals and ancil-
lary services. The nurses reported that a large portion of
their time was spent calling insurance providers rather
than providing patient care. The MCOs were viewed as
very bureaucratic; nurses had difficulty contacting the
right individual and getting answers to their questions.
The purpose of many telephone calls was justifying why
patients needed to have certain tests performed. Providers
felt that care was fragmented and uncoordinated when a
patient had to go to a primary care physician or to another
physician’s office for a referral, to another location for a
test, and then back to the oncologist for radiation or
chemotherapy. Providers also were concerned about their
patients having to return to the primary care provider for
follow-up care rather than being seen by the specialist.
The providers thought that personnel at MCOs did not
realize the burden that disjointed delivery of care placed
onpatients.Althoughmostpatientsinthestudywerecov-
ered by managed care insurance, medical providers
thought that the type of treatment received was based on
medical necessity, and they did not believe that treatment
was influenced by insurance type. In most cases, physi-
cians did not know what type of insurance a woman had.
However, physicians expressed concern about how the
lowering of cancer drug reimbursements may affect drug
choicesinsomepractices.
18Inaseparatesurveyofoncolo-
gists, 58% said they considered revenue when making
treatment recommendations.
25 If a particular treatment
would result in revenue loss, then most said they would
choose to refer patients to a hospital (69%) or would pre-
scribe an alternative medication (59%). In that survey,
76%ofrespondentsworkedinsmallcommunitypractices
(1-3physicians).
Pay for performance
A survey of 348 medical oncologists, radiation
oncologists, and surgeons was conducted in California in
2000toassesstheuseoffinancialincentivesrelatedtoper-
formance on quality measures. Overall, 35% of respond-
ents reported being subject to incentives based on quality
measures. Incentives were based on patient satisfaction
surveys for 20% of the 348 respondents and on other
quality measures, such as adherence to practice guidelines,
for 15% of the respondents. Physicians most likely to be
subject to quality incentives worked in staff-model or
group-model healthmaintenanceorganizationsorin large
practices (>50 physicians). Quality incentives were more
common among physicians who had a partial ownership
interest in their practice, those who were paid predomi-
nantly by means other than fee for service, and those who
werenot reimbursedthroughcapitation.
26
Managed Care/Reimbursement Perspective
Five sources presented views on quality cancer care from
leaders in managed care industries (Table 7). The number
of views represented was small; in 4 of the sources, only 6
leaders were interviewed or reported on their companies’
strategies to address quality while controlling costs. The
reportofresults fromthesurvey commissionedby Genen-
tech,
25 which was mailed to nearly 4000 managed care
professionals,didnotspecifythe numberofrespondents.
Cost-reduction strategies
Managing the availability of cancer treatment and
individual patients’ access to that treatment presents a sig-
nificant challenge to payers as the costs of cancer interven-
tions rise. Medical expenditures for cancer rank in the top
Table 6. Mean Number of Patients Cared for Per Shift by Registered Nurses in the Inpatient or Outpatient Setting and by
Oncology or Mixed Care Units
a
Employment Setting Mean No. of Patients
Actually Cared for
Per RN Per Shift
Mean No. of Patients
Judged by RN as
Appropriate Per Shift
Excess No. of
Patients Per
RN Per Shift
Inpatient dedicated oncology unit 5.26 3.97 1.29
Inpatient mixed unit 7.30 5.16 2.14
Outpatient dedicated oncology unit 18.70 12.25 6.45
Outpatient mixed unit 13.54 9.73 3.81
RN indicates registered nurse.
aSource: Lamkin 2002.
24
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27 Cancer chemother-
apy represents a large share of drug costs to payers. For
example, chemotherapy accounted for 35% to 40% of the
$300 million in drug costs that were covered under medi-
cal benefits for 1 payer located in the mid-Atlantic region
of the United States, and that payer’s chemotherapy costs
rose 25% each year.
28 Payers are seeking cost-reduction
strategies that still allow them to provide high-quality,
optimal,evidence-basedcare. Payersaremindfulof avoid-
ing adversarial relationships with patient advocacy groups
and themedia
27 andofmakingchanges thatleadtophysi-
cians withdrawing fromtheirnetworks.
25
Examples of specific strategies come from Blue
Cross Blue Shield (BCBS) of Florida (BCBSF),
29 which
has developed frequently updated, detailed drug coverage
guidelines; established its own care management program
(rather thanoutsourcingthisneed);and set upan ambula-
tory infusion suite network that reportedly is more cost-
effective than administering intravenous medications in a
hospital. BCBSF also is developing retrospective drug use
reviews to evaluate compliance with oral cancer drugs in
the hope that better compliance will lead to better out-
comes for patients with less cost to payers. To assist mem-
bers, BCBSF is developing a self-service shopping tool
that will allow members to view their copayment at vari-
ous pharmacies before they fill an oral cancer drug
prescription.
Clinical pathways are another tool that payers are
using to control costs by reducing variation in care. The
principle behind clinical pathways is that use of the same
proven treatment regimens by all providers may produce
more consistent outcomes and cost savings. Some of the
money saved can be given back to providers as incentives
for complying with the clinical pathways. The pathways
are developed by clinicians without payer involvement,
and complianceis monitoredthrough electronic claims. A
BCBS program (CareFirst) offers a higher reimbursement
rate for chemotherapy agents if physicians have at least a
65% compliance rate with chemotherapy regimens for
their patients overall. For supportive care, the minimum
accepted compliance rate is 80%. BCBS does not plan to
increase the minimum compliance for chemotherapy
beyond 90% given the individualized nature of cancer
treatment.
28
A clinical pathway program at the University of
Pittsburgh Medical Center uses a web-based decision sup-
port tool that is incorporated into the physician’s work-
flow by containing the list of patients the physician will
see and their histories related to the pathway. Decision
aids include standard regimen-order sets, standard dose
adjustments, patient education materials, and clinical trial
literature related to the pathway regimens. This pathways
program reportedly savedHighmarkBCBS$1million for
asinglebiologic(bevacizumab;GenentechInc.,SanFran-
cisco,Calif)within6months.
30
Increasing costs of oncology-related drugs
The NCCN discussed current practices with execu-
tives from 3 major MCOs to gain the payer’s perspective
on the rising cost of cancer treatment and to learn how
patients, providers, and industry might be affected.
27
Approaches varied among the 3 payers, with 1 payer
imposing few restrictions on oncology-related drugs. That
payer offered extensive coverage for cancer clinical trials
Table 7. Sources Reporting Perceptions of Managed Care Professional About Quality Cancer Care
Reference Source Study Design or Type of
Publication
Type of Professional Sample
Size
Genentech 2008
25 Survey/questionnaire Medical directors, pharmacy directors, clinical
pharmacists, other administrators; (>80% served
on P&T committees)
NR
a
NCCN 2009
27 Interview Senior managers from 3 managed care
organizations
3
2008
30 Interview Industry thought leader (Director of Medical Oncol-
ogy at Pittsburgh Medical Center Cancer Centers)
1
Wong 2008
28 Recounting of innovation impact on
quality of care
Vice president of pharmacy management at BCBS 1
Fenrick 2009
29 Recounting of innovation impact on
quality of care
Director of clinical pharmacy programs at BCBS of
Florida
1
Total no. of managed care
professionals/industry
thought leaders
 6
a
P&T indicates pharmacy and therapeutics; NR, not reported; NCCN, National Comprehensive Cancer Network; BCBS, Blue Cross Blue Shield.
aThe survey for Genentech was mailed to 3691 managed care professionals; the response rate was low, but the number of responses was not reported.
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when these were offered through its centers of excellence
programs (practices that have high-volume experience
with rare or complex cancers). The other payers required
precertification, especially of expensive biologics. The sec-
ond payer was considering proposals to manage cancer
drug costs by establishing tiers for infusible drugs, which
is a common practice with oral agents. In this approach,
the patient’s out-of-pocket costs increase with each tier
level of the prescribed drug. This payer also was consider-
ing ways to encourage physicians to obtain drugs through
a specialty pharmacy (eg, by limiting the reimbursement
for a particular drug to what it would cost from the spe-
cialtypharmacy).Thethirdpayermore closelyscrutinized
the chemotherapy doses and the types of drugs used in
combination regimens as a way to ensure that there was
less variability in care. In keeping with reducing variabili-
ty, this payer also was piloting an approach that reim-
bursed for an episode of care instead of directly
reimbursingforinfusiondrugs.
27
In a survey conducted for Genentech, 62% of
responding MCO professionals indicated that their com-
panies had created or planned to create separate benefit
designs for injectable specialty cancer drugs, putting them
on fourth and fifth tiers (with higher cost sharing for
patients).
25 MCO professionals believed that prior
authorizations were important or very important for lim-
iting the use of biologics or injectables to indications
approved by the US Food and Drug Administration
(FDA) (79% of respondents) or to indications described
in compendia (83%). Regarding reimbursements to prac-
tices for chemotherapy drugs, 53% of respondents had
adopted or planned to adopt reimbursement based on av-
erage sales price, a method chosen by Medicare in 2005
that provides lower reimbursements than were paid his-
torically. However, 57% of those who responded affirma-
tively to the question on average sales price did reimburse
or planned to reimburse at higher rates than Medicare.
Figure 2 provides a side-by-side summary of the patients’,
providers’, and managed care professionals’ perspectives
on managedcareintheoncologysetting.
DISCUSSION
In this literature review, we attempted to search the pub-
lished literature comprehensively for stakeholder percep-
tions on quality of cancer care regarding chemotherapy;
however, electronic searches have a limited capacity to cap-
ture all citations on a topic.
31 Despite this limitation, the
small number of studies that we identified probably was
because of the paucity of scientific exploration on the topic.
High-quality cancer care cannot be achieved without an
understanding of perceptions of quality. Efforts to under-
stand stakeholder needs better are even more essential
Figure 2. Managed care issues in oncology are listed from the point of view of patients, providers, and managed care organiza-
tions (MCOs).
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assure that quality of cancer care is maintained and
improved.
The quality of cancer care is under pressure in part
because of the rising number of cancer patients in the
United States.
32 Efforts to deliver quality cancer care also
will be challenged increasingly by a shortage of practi-
tionersand supportstaff,
33 especiallyas theadministrative
burden of managed care increases. By 2020, it is expected
that the shortage of oncologists in the United States will
be between 2350 and 3800, which represents a capacity of
between 9.5 million and 15 million office visits. This
workforce shortage largely will be caused by a slower
increase in the number of oncologists compared with the
increased demand.
4,5
Tocompensateforphysicianshortages,nursepracti-
tioners and physician assistants likely will be used increas-
ingly in the future.
34 Education programs must be
developed to address cancer-specific procedures, clinical
situations, and reimbursement issues as the roles of these
professionalsincancer careincrease.
35,36
The personal interactions that patients desire will
require changes in managed care processes and systems for
information gathering that increase the availability of pro-
viderstocareforpatients.Theassignmentofcasemanagers
can help patients navigate the extensive number of clinical,
financial, and reimbursement decisions; however, this
requires sufficient training of personnel, more uniformity
in procedures, and adequate funding by insurers. Scientific
evidence that case management can increase the efficiency
and quality of cancer care continues to be important in
bringingaboutchangeinthehealthcaresystem.
Current national legislative efforts to reform the US
healthcare system have several different goals, among
which are to increase access to affordable health insurance
and to control ongoing increases in healthcare costs. The
development and marketing of new cancer therapies does
not promise to make controlling healthcare costs any eas-
ier. The cost of innovative treatments is a concern for
payers, although clinical evidence often indicates that the
use of these treatments is appropriate. Payers are con-
cerned that physicians may choose the regimen that pro-
vides greater revenue for their practice, whereas physicians
have expressed (see Provider Prospective, above) that their
concern is with revenue loss from certain therapies, which
can makeitdifficulttosustaintheirpractices.
25,37
Current cancer drug reimbursement is rooted in the
system of compensating physicians for their time, which
relies on the Resource-Based Relative Value Scale
(RBRVS). This system discriminates against services in
which cognition is dominant, favoring reimbursement of
procedures and imaging over tasks such as supervising
nurses, contacting other treating physicians, and checking
laboratory results.
38 In the past, when oncologists could
make up lost earnings through higher drug reimburse-
ments,theywerenotasconcernedabouttheissueswiththe
RBRVS system. After Medicare tied drug reimbursements
to the actual average sales price of drugs in 2005, profit
marginsonchemotherapydecreased,andoncologistscould
no longer compensate for lost earnings.
38 Nongovernment
payers were slow to adopt Medicare reimbursement meth-
ods, but a growing number of those payers planned to
implementthesechangesin2007and2008.
39
Innovative cancer drugs can cost payers an addi-
tional $10,000 to $20,000 or more for just the initial
phase of treatment,
40 with higher costs incurred if the
agent is administered chronically. Payers require prior
authorizations to ensure that these drugs are used accord-
ing to FDA guidelines or compendia recommendations.
However, the cost of chemotherapy or supportive drugs
increases indirectly when considerable time is required to
fill out extensive prior authorization forms.
37 In addition,
requiring prior authorizations for various treatments
reducesthetimethatproviders,especiallynurses,canspend
with patients, which may negatively affect providers’ per-
ceptionsofthequalityofcaretheyadminister.
18
Patients’ abilities to comply with oncology prescrip-
tions also are affected by insurance policies, such as high
coinsurance. If patients cannot afford to pay their part,
then they may have to take a different medication that
may not be as effective, or they may not receive an onco-
logicagenttotreat theirdisease.
Physicians and patients may value newer agents and
regimens that extend life longer than established therapy
but that still do not offer substantial gains in life expect-
ancy (eg, just a few months of extra survival time).
Patients with cancer may be willing to take substantial fi-
nancial risks to extend their lives.
32 However, many
patients have fewer financial resources to risk; and, from
an ethical standpoint, access to beneficial therapies should
not be restricted to wealthier patients.
41 Instituting meas-
ures to satisfy the perceived needs identified in this study
areawayto assureimprovedqualityof cancercare.
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